These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33325645)

  • 1. Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.
    Miya A; Nakamura A; Cho KY; Kawata S; Nomoto H; Nagai S; Sugawara H; Taneda S; Tsuchida K; Omori K; Yokoyama H; Takeuchi J; Aoki S; Kurihara Y; Atsumi T; Miyoshi H
    J Diabetes Investig; 2021 Aug; 12(8):1395-1399. PubMed ID: 33325645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.
    Cho KY; Nomoto H; Nakamura A; Kawata S; Sugawara H; Takeuchi J; Nagai S; Omori K; Tsuchida K; Miya A; Shigesawa I; Tsuchida K; Yanagiya S; Kameda H; Yokoyama H; Taneda S; Kurihara Y; Aoki S; Nishimoto N; Atsumi T; Miyoshi H
    J Diabetes Investig; 2021 Aug; 12(8):1417-1424. PubMed ID: 33421309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).
    Cho KY; Nomoto H; Nakamura A; Kawata S; Sugawara H; Takeuchi J; Nagai S; Tsuchida K; Omori K; Yokoyama H; Manda N; Kurihara Y; Aoki S; Atsumi T; Miyoshi H
    Diabetes Obes Metab; 2020 Mar; 22(3):458-462. PubMed ID: 31486230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.
    Fushimi Y; Obata A; Sanada J; Iwamoto Y; Mashiko A; Horiya M; Mizoguchi-Tomita A; Nishioka M; Kan Y; Kinoshita T; Okauchi S; Hirukawa H; Kohara K; Tatsumi F; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Res; 2020; 2020():4861681. PubMed ID: 32337293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H
    Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
    Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
    J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Gouda M; Iijima H; Watanabe Y
    Diabetes Obes Metab; 2018 Feb; 20(2):453-457. PubMed ID: 28786530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of canagliflozin and teneligliptin on energy intake and body weight in Japanese patients with Type 2 diabetes: a subanalysis of the CANTABILE study.
    Isogawa M; Makino H; Son C; Nishimura K; Hirata T; Kasama S; Miyamoto Y; Noguchi M; Kasahara M; Hosoda K
    BMC Endocr Disord; 2024 Aug; 24(1):153. PubMed ID: 39160513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
    Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
    Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Iijima H; Watanabe Y; Gouda M
    Diabetes Obes Metab; 2017 Jun; 19(6):874-882. PubMed ID: 28177187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.
    Ito R; Fukui T; Hayashi T; Osamura A; Ohara M; Hara N; Higuchi A; Yamamoto T; Hirano T
    Drugs R D; 2015 Sep; 15(3):245-51. PubMed ID: 26224337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic insights from sequential combination therapy with a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin.
    Okahata S; Sakamoto K; Mitsumatsu T; Kondo Y; Tanaka S; Shiba T
    Diabetes Obes Metab; 2019 Feb; 21(2):388-392. PubMed ID: 30146790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of combination therapy of canagliflozin and teneligliptin on diabetic polyneuropathy and β-cell volume density in spontaneously type 2 diabetic Goto-Kakizaki rats.
    Guo D; Mizukami H; Osonoi S; Takahashi K; Ogasawara S; Kudo K; Sasaki T; Yagihashi S
    Metabolism; 2020 Jun; 107():154232. PubMed ID: 32302619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study.
    Son C; Makino H; Kasahara M; Tanaka T; Nishimura K; Taneda S; Nishimura T; Kasama S; Ogawa Y; Miyamoto Y; Hosoda K
    Diabetes Res Clin Pract; 2021 Oct; 180():109037. PubMed ID: 34481910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
    Tanaka S; Suzuki K; Aoki C; Niitani M; Kato K; Tomotsune T; Aso Y
    Diabetes Technol Ther; 2014 Dec; 16(12):840-5. PubMed ID: 25144424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.
    Kadowaki T; Inagaki N; Watada H; Sasaki K; Mori-Anai K; Iwasaki T; Teranishi T
    Adv Ther; 2022 Apr; 39(4):1642-1658. PubMed ID: 35138572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.
    Ceriello A; De Nigris V; Iijima H; Matsui T; Gouda M
    Drugs; 2019 May; 79(7):733-750. PubMed ID: 30982160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties.
    Kutoh E; Wada A; Terayama S
    Clin Drug Investig; 2016 Oct; 36(10):809-18. PubMed ID: 27352309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Yamada Y
    Adv Ther; 2020 May; 37(5):2477-2492. PubMed ID: 32323194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study.
    Okajima F; Nagamine T; Nakamura Y; Hattori N; Sugihara H; Emoto N
    J Diabetes Investig; 2017 May; 8(3):341-345. PubMed ID: 27762088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.